Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




May
19
Today In Oncology
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2 Positive Early Breast Cancer
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo